FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385988426> ?p ?o ?g. }

• W4385988426 abstract "Studies have investigated the efficacy and safety of switching to the biosimilar infliximab (CT-P13) in patients with inflammatory bowel disease (IBD). However, there is limited research directly comparing the effectiveness, drug survival, and pharmacokinetic profiles of the reference infliximab (IFX) and CT-P13 in real clinical settings.To compare the effectiveness and drug survival of CPT-13 and reference IFX at weeks 26 and 52, and to determine the pharmacokinetic profiles and safety profile in real-world settings.A retrospective observational cohort analysis was conducted at a single center. The study compared the proportion of patients achieving clinical remission and experiencing poor clinical outcomes at weeks 26 and 52. The drug survival rate of CT-P13 and reference infliximab was also assessed during the follow-up period.A total of 153 patients were included in the study, 39.2% receiving CPT-13 and 60.8% reference IFX. At week 26, clinical remission rates were 66.7% (CPT-13: 74.4% vs. reference IFX: 62.3%, p=0.178), and at week 52, they were 64% (CPT-13: 85.4% vs. reference IFX: 63.0%, p=0.012). Subgroup analysis with therapeutic drug monitoring (TDM) found no significant differences at week 26 (CPT-13: 74.4% vs. reference IFX: 58.8%, p=0.235) or at week 52 (CPT-13: 85.4% vs. reference IFX: 68.8%, p=0.153).Our study demonstrates comparable efficacy, drug survival, pharmacokinetic profiles, and incidence of immunogenicity between both drugs in a real clinical setting. Further studies with greater statistical power are needed to validate these findings." @default.
• W4385988426 created "2023-08-19" @default.
• W4385988426 creator A5019126200 @default.
• W4385988426 creator A5051308512 @default.
• W4385988426 creator A5053779043 @default.
• W4385988426 creator A5053918633 @default.
• W4385988426 creator A5071326083 @default.
• W4385988426 creator A5079207747 @default.
• W4385988426 date "2023-08-01" @default.
• W4385988426 modified "2023-10-14" @default.
• W4385988426 title "Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study" @default.
• W4385988426 cites W2102013054 @default.
• W4385988426 cites W2121050884 @default.
• W4385988426 cites W2149858688 @default.
• W4385988426 cites W2162768160 @default.
• W4385988426 cites W2171297959 @default.
• W4385988426 cites W2323925800 @default.
• W4385988426 cites W2342216265 @default.
• W4385988426 cites W2342464058 @default.
• W4385988426 cites W2345220764 @default.
• W4385988426 cites W2589358629 @default.
• W4385988426 cites W2613299853 @default.
• W4385988426 cites W2624671969 @default.
• W4385988426 cites W2733544055 @default.
• W4385988426 cites W2751387666 @default.
• W4385988426 cites W2754783592 @default.
• W4385988426 cites W2764071025 @default.
• W4385988426 cites W2799527746 @default.
• W4385988426 cites W2801351505 @default.
• W4385988426 cites W2801647441 @default.
• W4385988426 cites W2892075969 @default.
• W4385988426 cites W2904014975 @default.
• W4385988426 cites W2923576761 @default.
• W4385988426 cites W2923675504 @default.
• W4385988426 cites W2938260764 @default.
• W4385988426 cites W2976531769 @default.
• W4385988426 cites W3190445083 @default.
• W4385988426 doi "https://doi.org/10.1016/j.gastrohep.2023.08.004" @default.
• W4385988426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37597745" @default.
• W4385988426 hasPublicationYear "2023" @default.
• W4385988426 type Work @default.
• W4385988426 citedByCount "0" @default.
• W4385988426 crossrefType "journal-article" @default.
• W4385988426 hasAuthorship W4385988426A5019126200 @default.
• W4385988426 hasAuthorship W4385988426A5051308512 @default.
• W4385988426 hasAuthorship W4385988426A5053779043 @default.
• W4385988426 hasAuthorship W4385988426A5053918633 @default.
• W4385988426 hasAuthorship W4385988426A5071326083 @default.
• W4385988426 hasAuthorship W4385988426A5079207747 @default.
• W4385988426 hasConcept C112705442 @default.
• W4385988426 hasConcept C126322002 @default.
• W4385988426 hasConcept C167135981 @default.
• W4385988426 hasConcept C2777138892 @default.
• W4385988426 hasConcept C2778260677 @default.
• W4385988426 hasConcept C2779134260 @default.
• W4385988426 hasConcept C2780272996 @default.
• W4385988426 hasConcept C59491497 @default.
• W4385988426 hasConcept C71924100 @default.
• W4385988426 hasConcept C72563966 @default.
• W4385988426 hasConcept C90924648 @default.
• W4385988426 hasConceptScore W4385988426C112705442 @default.
• W4385988426 hasConceptScore W4385988426C126322002 @default.
• W4385988426 hasConceptScore W4385988426C167135981 @default.
• W4385988426 hasConceptScore W4385988426C2777138892 @default.
• W4385988426 hasConceptScore W4385988426C2778260677 @default.
• W4385988426 hasConceptScore W4385988426C2779134260 @default.
• W4385988426 hasConceptScore W4385988426C2780272996 @default.
• W4385988426 hasConceptScore W4385988426C59491497 @default.
• W4385988426 hasConceptScore W4385988426C71924100 @default.
• W4385988426 hasConceptScore W4385988426C72563966 @default.
• W4385988426 hasConceptScore W4385988426C90924648 @default.
• W4385988426 hasLocation W43859884261 @default.
• W4385988426 hasLocation W43859884262 @default.
• W4385988426 hasOpenAccess W4385988426 @default.
• W4385988426 hasPrimaryLocation W43859884261 @default.
• W4385988426 hasRelatedWork W1981336058 @default.
• W4385988426 hasRelatedWork W2587157414 @default.
• W4385988426 hasRelatedWork W2744741840 @default.
• W4385988426 hasRelatedWork W2774189845 @default.
• W4385988426 hasRelatedWork W2914211697 @default.
• W4385988426 hasRelatedWork W2924476097 @default.
• W4385988426 hasRelatedWork W2951297589 @default.
• W4385988426 hasRelatedWork W3010465489 @default.
• W4385988426 hasRelatedWork W4220693647 @default.
• W4385988426 hasRelatedWork W4283374778 @default.
• W4385988426 isParatext "false" @default.
• W4385988426 isRetracted "false" @default.
• W4385988426 workType "article" @default.